Supreme Court ruling blocks thousands of lawsuits against maker of Roundup weedkiller

The Supreme Court sided with the maker of the Roundup weedkiller Thursday in a ruling expected to block thousands of lawsuits alleging it failed to warn people the product could cause cancer.

The case came before the justices after a tidal wave of litigation that included some multibillion-dollar verdicts against the global agrochemical manufacturer Bayer, which acquired Roundup when it bought its original manufacturer Monsanto in 2018.

The decision is a victory for the Trump administration, but one that could be tricky politically since allies in the Make America Healthy Again movement want to rein in pesticide use.

The high court, in a 7-2 ruling, found that the company can’t be sued in state courts because federal regulations have found a cancer link unlikely and do not require a warning label.

The decision “is good for science, farmers, and industries that depend on regulatory clarity for innovation,” Bayer said in a statement. “It should help significantly contain the Roundup litigation after nearly a decade of legal battles.”

Though Bayer said the ruling should result in the dismissal of pending lawsuits containing failure-to-warn allegations, the company said it plans to proceed with a proposed $7.25 billion class-action settlement intended to resolve many of the remaining claims.

Lawyers for some residents pursuing Roundup litigation criticized the court’s decision.

“This Supreme Court ruling wrongly slams the courthouse door on Americans sickened by pesticides,” said attorney Christopher Seeger, who is proposed as a claimants’ representative in the settlement. But he said a settlement still would allow some people to receive compensation.

The case before the Supreme Court was filed by Missouri resident John Durnell. He developed a cancer called non-Hodgkin’s lymphoma after more than 20 years of serving as the neighborhood association’s “spray guy,” using Roundup on parks in his historic St. Louis community.

A jury agreed that the company failed to warn him about possible cancer dangers and awarded him $1.25 million. It’s one of thousands of similar cases, including some multibillion-dollar damage awards.

For Subscribers

FOR SUBSCRIBERSTrump promised $2 gas and cheaper groceries. Here’s what voters got.

FOR SUBSCRIBERSHe’s in the West Wing. He’s at the rally. He’s got Trump’s ear. Bill Pulte is everywhere.

FOR SUBSCRIBERSNew AI tool for voters offers a specialized chatbot to explain your ballot

FOR SUBSCRIBERSGOP retreats from North Carolina as Trump admits Democrats likely to win Senate seat

FOR SUBSCRIBERSNetflix’s latest cliff-hanger? Where it’s headed as a business

FOR SUBSCRIBERSOpenAI agents are shutting off ways to monitor misbehavior

FOR SUBSCRIBERSWhy John Turturro is having the best year of any New Yorker

FOR SUBSCRIBERSJames Talarico digs in with Black voters in pursuit of an elusive Democratic win in Texas

FOR SUBSCRIBERSRussian operatives likely spread fake videos targeting the Texas Senate race, researchers say

FOR SUBSCRIBERSRepublicans seek inroads with Black voters in Michigan’s tight Senate race

FOR SUBSCRIBERSEurope’s protests are about more than schools — they’re a generational roar

FOR SUBSCRIBERSTrump is desperate to bring gas prices down. The solution might be in India.

FOR SUBSCRIBERSInteractive map: How far do you live from the nearest data center?

FOR SUBSCRIBERSA decade ago, data centers overtook a rural community. It hasn’t been the same since.

FOR SUBSCRIBERSiPhone Duo review: The good, the bad and the buggy

Slide 1 of 1

For Subscribers

FOR SUBSCRIBERSTrump promised $2 gas and cheaper groceries. Here’s what voters got.

FOR SUBSCRIBERSHe’s in the West Wing. He’s at the rally. He’s got Trump’s ear. Bill Pulte is everywhere.

FOR SUBSCRIBERSNew AI tool for voters offers a specialized chatbot to explain your ballot

FOR SUBSCRIBERSGOP retreats from North Carolina as Trump admits Democrats likely to win Senate seat

FOR SUBSCRIBERSNetflix’s latest cliff-hanger? Where it’s headed as a business

FOR SUBSCRIBERSOpenAI agents are shutting off ways to monitor misbehavior

FOR SUBSCRIBERSWhy John Turturro is having the best year of any New Yorker

FOR SUBSCRIBERSJames Talarico digs in with Black voters in pursuit of an elusive Democratic win in Texas

FOR SUBSCRIBERSRussian operatives likely spread fake videos targeting the Texas Senate race, researchers say

FOR SUBSCRIBERSRepublicans seek inroads with Black voters in Michigan’s tight Senate race

FOR SUBSCRIBERSEurope’s protests are about more than schools — they’re a generational roar

FOR SUBSCRIBERSTrump is desperate to bring gas prices down. The solution might be in India.

FOR SUBSCRIBERSInteractive map: How far do you live from the nearest data center?

FOR SUBSCRIBERSA decade ago, data centers overtook a rural community. It hasn’t been the same since.

FOR SUBSCRIBERSiPhone Duo review: The good, the bad and the buggy

Slide 1 of 1

There’s still fierce debate about cancer and Roundup’s key ingredient, glyphosate. The World Health Organization’s International Agency for Research on Cancer classified the chemical as “probably carcinogenic” in 2015. The Environmental Protection Agency has determined that it’s not likely to cause cancer in humans when used as directed.

The agency approved a label without a cancer warning, and Bayer argues that it’s required to follow those federal standards — not the state laws that Durnell and others have sued under. The ruling still could allow other suits alleging problems with the way the product was designed, his attorney Ashley Keller has said.

Bayer disputes the cancer claims but previously set aside $16 billion to settle cases, and earlier this year proposed a $7.25 billion class-action settlement. A federal judge recently ruled that the proposed settlement will be heard in a Missouri state court, where many of the lawsuits have been filed. At the same time, the company has tried to persuade states to pass laws shielding it from liability in failure-to-warn lawsuits, and three states have agreed.

About 200,000 Roundup-related claims have been made against Bayer, mostly from home users. It has stopped using glyphosate in Roundup sold in the U.S. residential lawn and garden market.

The company has said it might have to consider pulling glyphosate from U.S. agricultural markets if it keeps getting sued. Agricultural industry group say could have a devastating effect on the food supply.

But pesticides have also created a rift between the Trump administration and members of Health Secretary Robert F. Kennedy’s MAHA movement, adding to their frustration with an executive order aimed at boosting glyphosate’s production.

Kennedy himself has said repeatedly that glyphosate causes cancer, even as he says he recognizes the executive order was necessary for food supply and national security reasons.